A detailed history of Cambridge Trust CO transactions in Biogen Inc. stock. As of the latest transaction made, Cambridge Trust CO holds 335 shares of BIIB stock, worth $58,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares
335
Previous 335 -0.0%
Holding current value
$58,219
Previous $86,000 16.28%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 25, 2023

SELL
$275.25 - $318.06 $17,065 - $19,719
-62 Reduced 15.62%
335 $95,000
Q4 2022

Jan 09, 2023

SELL
$252.44 - $306.72 $504 - $613
-2 Reduced 0.5%
397 $110,000
Q3 2022

Nov 07, 2022

BUY
$194.69 - $268.46 $389 - $536
2 Added 0.5%
399 $107,000
Q2 2022

Aug 16, 2022

BUY
$187.54 - $223.02 $11,627 - $13,827
62 Added 18.51%
397 $81,000
Q1 2022

May 12, 2022

SELL
$193.77 - $244.14 $6,394 - $8,056
-33 Reduced 8.97%
335 $71,000
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $82,402 - $105,899
368 New
368 $88,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Cambridge Trust CO Portfolio

Follow Cambridge Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Trust CO with notifications on news.